Contrast medium injection protocol adjusted for body surface area in combined PET/CT

Abstract

• Intravenous contrast medium is essential for many applications of PET/CT • Body surface area adjustment of contrast medium helps standardise contrast enhancement • Underdosing or overdosing of contrast medium will be reduced • PET image quality is not influenced • BSA adjusted contrast medium protocol should be used preferably in combined PET/CT.

Body surface area adapted iopromide 300mg/ml versus 370mg/ml contrast medium injection protocol: Influence on quantitative and clinical assessment in combined PET/CT

“…However, in line with other literature we also showed that these differences are not clinically relevant [8][9][10][11][12][13].…”

“…However, the use of ceCT, especially when used for attenuation correction of the PET dataset, may be associated with reconstruction artifacts in which contrast enhanced structures are displayed with erroneously high tracer uptake values [6,7]. Fortunately, an increasing body of evidence in literature shows that, although statistically significant, such influences likely are not clinically relevant [8][9][10][11][12][13].…”

No clinically relevant differences between positron emission tomography (PET) reconstructions based on low‐dose or contrast‐enhanced CT in combined integrated multiphase 18F‐Fluorethylcholine PET/CT for prostate cancer

“…To the best of our knowledge, the effects of the use of ceCT in PET reconstruction in FCH‐PET/CT have not been studied before. However, in FDG PET/CT it has been shown that no significant quantitative or qualitative differences in PET reconstruction resulted from the use of different contrast medium injection protocols . The present results echo those of studies performed in FDG PET/CT, where similar statistically significant, but not clinically relevant increases in quantitative measures of radionuclide uptake were observed .…”

“…However, the use of ceCT for attenuation correction in PET/CT may be associated with reconstruction artefacts such as erroneously high tracer uptake values for contrast‐enhanced structures . At least for 18 F‐2‐deoxy‐fluoroglucose (FDG) PET/CT, a number of studies have shown that such influence may be statistically significant but lack clinical relevance …”

“…8,9 At least for 18 F-2-deoxyfluoroglucose (FDG) PET/CT, a number of studies have shown that such influence may be statistically significant but lack clinical relevance. [10][11][12][13][14][15] However, in prostate cancer patients, typical lymph node metastases are quite often small and can show only minor contrast with the surrounding background. Therefore, even minor changes in the reconstructed FCH distribution could conceivably lead to differences in the clinical assessment of PCA patients.…”